Financhill
Sell
29

PPH Quote, Financials, Valuation and Earnings

Last price:
$86.76
Seasonality move :
2.83%
Day range:
$85.97 - $87.24
52-week range:
$80.52 - $99.51
Dividend yield:
1.86%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
193.4K
Avg. volume:
194.9K
1-year change:
8.84%
Market cap:
--
Revenue:
--
EPS (TTM):
--

Analysts' Opinion

  • Consensus Rating
    VanEck Pharmaceutical ETF has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Downside
    According to analysts' consensus price target of --, VanEck Pharmaceutical ETF has an estimated downside of -- from its current price of $86.54.
  • Price Target Upside
    According to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $86.54.

Fair Value

  • According to the consensus of 0 analysts, VanEck Pharmaceutical ETF has -- downside to fair value with a price target of -- per share.

PPH vs. S&P 500

  • Over the past 5 trading days, VanEck Pharmaceutical ETF has overperformed the S&P 500 by 0.54% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • VanEck Pharmaceutical ETF does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • VanEck Pharmaceutical ETF has grown year-over-year revenues for 0 quarters straight. In the most recent quarter VanEck Pharmaceutical ETF reported revenues of --.

Earnings Growth

  • VanEck Pharmaceutical ETF has grown year-over-year earnings for 0 quarters straight. In the most recent quarter VanEck Pharmaceutical ETF reported earnings per share of --.
Enterprise value:
--
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-23 2023-12-23 2023-12-23
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -- -- -- -- --
EBITDA -- -- -- -- --
Diluted EPS -- -- -- -- --
Period Ending 2020-12-23 2021-12-23 2022-12-23 2023-12-23
Balance Sheet
Current Assets -- -- -- -- --
Total Assets -- -- -- -- --
Current Liabilities -- -- -- -- --
Total Liabilities -- -- -- -- --
Total Equity -- -- -- -- --
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-23 2023-12-23 2023-12-23
Cash Flow Statement
Cash Flow Operations -- -- -- -- --
Cash From Investing -- -- -- -- --
Cash From Financing -- -- -- -- --
Free Cash Flow -- -- -- -- --
PPH
Sector
Market Cap
--
--
Price % of 52-Week High
86.97%
--
Dividend Yield
1.86%
--
Shareholder Yield
--
--
1-Year Price Total Return
8.84%
--
Beta (5-Year)
0.666
--
Dividend yield:
1.86%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $87.63
200-day SMA
Sell
Level $91.59
Bollinger Bands (100)
Sell
Level 89.54 - 96.7
Chaikin Money Flow
Buy
Level 22.2M
20-day SMA
Sell
Level $88.91
Relative Strength Index (RSI14)
Sell
Level 34.24
ADX Line
Sell
Level 13.78
Williams %R
Buy
Level -88.4166
50-day SMA
Sell
Level $90.32
MACD (12, 26)
Sell
Level -0.85
25-day Aroon Oscillator
Sell
Level -52
On Balance Volume
Neutral
Level 12.1M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (7)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Stock Forecast FAQ

In the current month, PPH has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PPH average analyst price target in the past 3 months is --.

  • Where Will VanEck Pharmaceutical ETF Stock Be In 1 Year?

    According to analysts, the consensus estimate is that VanEck Pharmaceutical ETF share price will drop to -- per share over the next 12 months.

  • What Do Analysts Say About VanEck Pharmaceutical ETF?

    Analysts are divided on their view about VanEck Pharmaceutical ETF share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that VanEck Pharmaceutical ETF is a Sell and believe this share price will rise from its current level to --.

  • What Is VanEck Pharmaceutical ETF's Price Target?

    The price target for VanEck Pharmaceutical ETF over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is PPH A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for VanEck Pharmaceutical ETF is a Buy. 0 of 0 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of PPH?

    You can purchase shares of VanEck Pharmaceutical ETF via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase VanEck Pharmaceutical ETF shares.

  • What Is The VanEck Pharmaceutical ETF Share Price Today?

    VanEck Pharmaceutical ETF was last trading at $86.76 per share. This represents the most recent stock quote for VanEck Pharmaceutical ETF. Yesterday, VanEck Pharmaceutical ETF closed at $86.54 per share.

  • How To Buy VanEck Pharmaceutical ETF Stock Online?

    In order to purchase VanEck Pharmaceutical ETF stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is up 0.73% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 6.55% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 5.65% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock